Emerging research suggests GLP-1 receptor agonists like semaglutide and tirzepatide may reduce cravings for alcohol and other substances by modulating dopamine signaling in the brain’s reward circuitry — the same “food noise” mechanism that drives weight-loss outcomes. No GLP-1 is FDA-approved for any addiction indication. This guide explains what the human evidence actually shows, substance by substance, and how PlexusDx Weight Management Protocols are positioned for chronic weight management only.